Equities analysts predict that Blueprint Medicines Corp (NASDAQ:BPMC) will post sales of $3.75 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $6.50 million. Blueprint Medicines posted sales of $41.44 million during the same quarter last year, which suggests a negative year-over-year growth rate of 91%. The company is scheduled to report its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that Blueprint Medicines will report full-year sales of $8.90 million for the current financial year, with estimates ranging from $3.90 million to $20.00 million. For the next financial year, analysts expect that the business will post sales of $42.62 million, with estimates ranging from $17.48 million to $62.62 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.15). The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.38 million. Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. Blueprint Medicines’s revenue was down 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.29) earnings per share.
NASDAQ:BPMC opened at $94.33 on Friday. The business’s 50-day moving average price is $85.54. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -17.50 and a beta of 1.45. Blueprint Medicines has a 52-week low of $44.58 and a 52-week high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27.
In related news, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $84.75, for a total value of $1,695,000.00. Following the transaction, the chief executive officer now owns 48,961 shares of the company’s stock, valued at approximately $4,149,444.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 2,733 shares of Blueprint Medicines stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $88.04, for a total value of $240,613.32. The disclosure for this sale can be found here. Insiders sold a total of 79,044 shares of company stock worth $7,077,431 in the last three months. 3.15% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in BPMC. Rhumbline Advisers increased its stake in shares of Blueprint Medicines by 46.1% in the fourth quarter. Rhumbline Advisers now owns 55,349 shares of the biotechnology company’s stock worth $2,984,000 after acquiring an additional 17,475 shares during the period. Comerica Bank increased its stake in shares of Blueprint Medicines by 20.9% in the fourth quarter. Comerica Bank now owns 12,617 shares of the biotechnology company’s stock worth $878,000 after acquiring an additional 2,180 shares during the period. First Trust Advisors LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $1,390,000. Dimensional Fund Advisors LP acquired a new stake in shares of Blueprint Medicines in the fourth quarter worth $1,352,000. Finally, Foresite Capital Management III LLC increased its stake in shares of Blueprint Medicines by 133.8% in the fourth quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock worth $25,213,000 after acquiring an additional 267,682 shares during the period. 97.46% of the stock is currently owned by institutional investors.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Story: What do investors mean by earnings per share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.